CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agilis Biotherapeutics, LLC, a synthetic biology-based company focused on developing DNA-based therapeutics for rare genetic diseases, announced today that Greg Robinson, Ph.D., has been named Chief Scientific Officer of the Company. Dr. Robinson brings more than 20 years of pharmaceutical and biotech experience in research, clinical development, R & D management and business roles to Agilis, having spent the last seven years at Shire PLC (LSE:SHP; NASDAQ GS:SHPG) where he served as Head of Discovery Research and more recently as Senior Director, Shire Rare Diseases Business Development.
